Press releases
- Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
- Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
- Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
- Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Key statistics
As of last trade, Sangamo Therapeutics Inc (GBY:DUS) traded at 0.31, 13.93% above the 52 week low of 0.2721 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.31 |
---|---|
High | 0.31 |
Low | 0.31 |
Bid | 0.31 |
Offer | 0.3133 |
Previous close | 0.3085 |
Average volume | 1.28k |
---|---|
Shares outstanding | 207.51m |
Free float | 191.47m |
P/E (TTM) | -- |
Market cap | 66.82m USD |
EPS (TTM) | -1.86 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 08:31 BST.
More ▼